DLL4: A Key Target for Angiogenesis RegulationRecently, Co.unlink Medicines and Compass Therapeutics announced that the phase II/III clinical trials of the VEGF/DLL4 bispecific antibody tovecimig (CTX-009/ES104) for second-line cholangiocarcinoma treatment have reac... Detailed information